The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | CA057-003 trial preliminary results: mezigdomide in novel combinations for R/R multiple myeloma
In this video, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, presents results from the CA057-003 study (NCT05372354), which is assessing a mezigdomide and dexamethasone (MEZId) backbone in combination with oral agents in the treatment of relapsed/refractory (R/R) multiple myeloma. In this study, MEZId was combined with tazemetostat, BMS-986158, or trametinib and demonstrated activity in heavily pretreated patients. Dr Costa comments on how these combinations may have the potential to overcome intrinsic drug resistance and provide an alternative approach for patients with limited treatment options. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
